64988-71-2

Usage

Uses

Used in Pharmaceutical Industry:
Isoxazole, 5-(chloromethyl)-3-(1-methylethyl)(9CI) is used as a synthetic intermediate for the development of pharmaceuticals, leveraging its unique structure and functional groups to create novel drug candidates.
Used in Agrochemical Industry:
Isoxazole, 5-(chloromethyl)-3-(1-methylethyl)(9CI) is utilized as a building block in the synthesis of agrochemicals, potentially contributing to the development of new pesticides or other agricultural products.
Used in Antimicrobial Applications:
Isoxazole, 5-(chloromethyl)-3-(1-methylethyl)(9CI) is employed as an antimicrobial agent, harnessing its ability to combat various microorganisms and contributing to the development of new treatments for infectious diseases.
Used in Antifungal Applications:
It serves as an antifungal agent, helping to inhibit the growth of fungi and offering potential solutions for treating fungal infections.
Used in Anticancer Applications:
Isoxazole, 5-(chloromethyl)-3-(1-methylethyl)(9CI) is explored for its anticancer properties, with the potential to be developed into a therapeutic agent targeting various types of cancer.
Note: The specific application reasons and industries are inferred from the general information provided about the compound's potential uses and properties. Further research and development would be necessary to confirm these applications and their effectiveness.

InChI:InChI=1/C7H10ClNO/c1-5(2)7-3-6(4-8)10-9-7/h3,5H,4H2,1-2H3

Upstream product

• 64988-80-3 5,6-dichloro-2-methyl-hex-4-en-3-one 
• 151-00-8 isobutyraldehyde oxime 
• 624-65-7 2-propynyl chloride 
• 14633-17-1 (3-isopropylisooxazol-5-yl)methanol 
• 121604-54-4 (3-isopropylisoxazol-5-yl)formaldehyde 

Relevant academic research and scientific papers

HYDROXYL PURINE COMPOUNDS AND USE THEREOF

Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.

Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents

A series of N-heterocyclic indolyl glyoxylamides were synthesized and evaluated for in vitro and in vivo anticancer activities. They exhibited a broad spectrum of anticancer activity not only in murine leukemic cancer cells but also in human gastric, breast, and uterus cancer cells as well as their multidrug resistant sublines with a wide range of IC50 values. They also induced apoptosis and caused DNA fragmentation in human gastric cancer cells. Among the compounds studied, 7 showed the most potent activity of growth inhibition (IC50 17-1711 nM) in several human cancer cells. Given orally, compounds 7 and 13 dose-dependently prolonged the survival of animals inoculated with P388 leukemic cancer cells. N-Heterocyclic indolyl glyoxylamides may be useful as orally active chemotherapeutic agents against cancer and refractory cancerous diseases of multidrug resistance phenotype.

Synthesis and properties of 3-alkyl(aryl)-5-chloromethylisoxazoles

3-Chloro-2-isothiocyanato-1-propenyl alkyl(aryl) ketones react with hydroxylamine hydrochloride to give 3-alkyl(aryl)-5-chloromethylisoxazole. Treatment of the latter with dimethylamine and ammonium thiocyanate leads to formation of previously unknown 3-alkyl(aryl)-5-dimethylamino(or isothiocyanato)-methylisoxazoles.